SCHEMBL379728

SCHEMBL379728

NNc1cc(Br)ccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397524 0.77
SCHEMBL1133522 0.77
SCHEMBL8501065 0.77
SCHEMBL8501063 0.77
SCHEMBL30477820 0.77
SCHEMBL1759892 0.74 GOT1 (0.37)
SCHEMBL2779409 0.74 RIOK2 (0.43)
SCHEMBL1963959 0.73
SCHEMBL30987267 0.73
SCHEMBL960313 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055016-B1 GPR52 MODULATOR COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-04-29 EP disclosed
EP-4711372-A1 CRYSTAL FORM OF HETEROCYCLIC COMPOUND, SALT THEREOF, CRYSTAL FORM OF SALT THEREOF, AND USE Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2026-03-18 EP disclosed
EP-4688777-A1 NOVEL PD-L1 INHIBITORS Affirma Biotech S. L. (ES) 2026-02-11 EP disclosed
US-20260035363-A1 COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2026-02-05 US disclosed
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 EP disclosed
US-12459933-B2 Compounds and methods of use thereof as antibacterial agents MERCK SHARP & DOHME LLC (US) 2025-11-04 US disclosed
US-20250326749-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-20250236619-A1 FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-07-24 US disclosed
EP-4536655-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF Sionna Therapeutics Inc. (US) 2025-04-16 EP disclosed
CN-119677730-A Compounds, compositions, and methods of use thereof 希安纳医疗公司 2025-03-21 CN disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
WO-2009126861-A2 TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-15 WO disclosed
WO-2009126861-A2 TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-15 WO disclosed
EP-2086973-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF Amgen Inc., (US) 2009-08-12 EP disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed